Search

Your search keyword '"Vicente Alberola"' showing total 15 results

Search Constraints

Start Over You searched for: Author "Vicente Alberola" Remove constraint Author: "Vicente Alberola" Journal lung cancer Remove constraint Journal: lung cancer
15 results on '"Vicente Alberola"'

Search Results

1. PD-004 Serum levels of vascular endothelial growth factor andepidermal growth factor receptor in advanced non-small cell lung cancer: Its correlation with clinical characteristics

2. PD-042 Induction (I) or consolidation (C) chemotherapy withdocetaxel (D) and gemcitabine (G) plus concomitant chemoradiotherapy (CT/TRT) with docetaxel and carboplatin (Cb) for unresectable stage III non-small cell lung cancer (NSCLC) patients (p). Initial report of the randomized phase II trial SLCG 0008

Catalog

Books, media, physical & digital resources

3. P-561 14-3-3 sigma (σ) methylation (M) in pre-treatment serum DNAof cisplatin (cis)/gemcitabine (gem)-treated non-small-cell lung cancer (NSCLC)

4. PD-149 Epidermal growth factor receptor (EGFR)-activating mutations(mut) and response to gefitinib in lung adenocarcinomas

5. O-47 XPD polymorphisms identify a subset of non-small-cell lung cancer (NSCLC) patients (p) with poor survival with gemcitabine (gem)/cisplatin (cis)

6. E-62. Pharmacogenomics: Individualized therapy

7. P-224 XPD polymorphisms in cisplatin (cis)/vinorelbine (vrb)-treated stage IV non-small-cell lung cancer (NSCLC) patients (p): genetic analysis of a Spanish Lung Cancer Group phase II trial

8. P-206 Comorbidity assessment in frail patients with advanced non-small cell lung cancer (NSCLC) treated with low-dose of weekly paclitaxel (WP)

9. Navelbine: The European experience in non small cell lung carcinoma (NSCLC)

10. Assessment of tubulin mutations in a phase II study of biweekly gemcitabine/paclitaxel (T) in advanced non-small-cell lung cancer (NSCLC)

11. Cisplatin/gemcitabine (CG) vs cisplatin/gemcitabine/vinorelbine (CGV) vs sequential doublets of gemcitabine/vinorelbine followed by ifosfamide/vinorelbine (GV/IV) in advanced non-small cell lung cancer. Interim analysis of a Spanish Lung Cancer Group (SLCG) phase III trial

12. 43 β-Tubulin gene mutation-mediated paclitaxel resistance in non-small cell lung cancer (NSCLC)

13. 39 Six year follow up of the European Multicentre Randomised Study comparing Navelbine (NVB) alone vs NVB + Cisplatin (CDDP) vs Vindesine (VDS) + CDDP in 612 patients (pts) with advanced non-small cell lung cancer (NSCLC)

14. 27 Gemcitabine plus cisplatin versus etoposide plus cisplatin in advanced non-small cell lung cancer: A randomized trial by the Spanish lung cancer group

15. 243 Spanish lung cancer group randomized trial of preoperative chemotherapy (cisplatin either 50 mg/m2 or 100 mg/m2) in stage IIIA (N2) non-small cell lung cancer (NSCLC)